Recurrent GBM brain tumors with few mutations respond best to immunotherapy
E-Mail DURHAM, N.C. - Glioblastoma brain tumors are especially perplexing. Inevitably lethal, the tumors occasionally respond to new immunotherapies after they've grown back, enabling up to 20% of patients to live well beyond predicted survival times. What causes this effect has long been the pursuit of researchers hoping to harness immunotherapies to extend more lives. New insights from a team led by Duke's Preston Robert Tisch Brain Tumor Center provide potential answers. The team found that recurring glioblastoma tumors with very few mutations are far more vulnerable to immunotherapies ...
Source: eurekalert.org